Arndt Vogel: Off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC JAMA Oncology.

Arndt Vogel, made the following post on Twitter:

“Off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC JAMA Oncology.

• ORR: 14.3% vs 5.4%
• mOS: 15.9 vs 14.1mo
• non-inferiority, in line with Nivo & Durva, but we need a “niche” or a biomarker…”

For details click here.
Source: Arndt Vogel/Twitter

Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.